Home › Research › Inflammation and the immune system
Volatile oil of Acori tatarinowii rhizoma: potential candidate drugs for mitigating dementia
Yifan Bu, Songzhe Li, Ting Ye, Yuqing Wang, Mingrong Song, Jing Chen. Frontiers in Pharmacology, 2025-04-23
Topic: Brain proteins, microglia and lab models
Plain-language summary
The volatile oil of ATR mitigates dementia through multiple pathways, including reducing abnormal protein aggregation, promoting neurogenesis, inhibiting neuronal apoptosis, regulating neurotransmitters, improving synaptic function, modulating autophagy, countering cellular stress, reducing neuroinflammation, and alleviating vascular risk factors. The multi-pathway pharmacological effects of the volatile oil of ATR are well-aligned with the complex mechanisms of dementia progression, highlighting its significant therapeutic potential for anti-dementia applications. This provides new perspectives for the development of more effective anti-dementia drugs. Nonetheless, further rigorous and high-quality preclinical and clinical investigations are required to address key issues, including the chemical characterization of the volatile oil of ATR, potential synergistic effects among active ingredients, toxicity profiles, and definitive clinical efficacy.
What this study adds
Evidence grade: Low
This review describes how the volatile oil of Acori tatarinowii rhizoma may affect dementia through multiple pathways. The text states that further rigorous preclinical and clinical investigations are required, so no treatment or prevention benefit is established.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bu, Y., Li, S., Ye, T., Wang, Y., Song, M., & Chen, J. (2025). Volatile oil of Acori tatarinowii rhizoma: potential candidate drugs for mitigating dementia. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1552801
Vancouver
Bu Y, Li S, Ye T, Wang Y, Song M, Chen J. Volatile oil of Acori tatarinowii rhizoma: potential candidate drugs for mitigating dementia. Frontiers in Pharmacology. 2025. doi:10.3389/fphar.2025.1552801. PMID: 40337511.
BibTeX
@article{bu2025-40337511,
author = {Bu, Yifan and Li, Songzhe and Ye, Ting and Wang, Yuqing and Song, Mingrong and Chen, Jing},
title = {{Volatile oil of Acori tatarinowii rhizoma: potential candidate drugs for mitigating dementia}},
journal = {Frontiers in Pharmacology},
year = {2025},
doi = {10.3389/fphar.2025.1552801},
pmid = {40337511},
url = {https://doi.org/10.3389/fphar.2025.1552801}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The volatile oil of ATR mitigates dementia through multiple pathways, including reducing abnormal protein aggregation, promoting neurogenesis, inhibiting neuronal apoptosis, regulating neurotransmitters, improving synaptic function, modulating autophagy, countering cellular stress, reducing neuroinflammation, and alleviating vascular risk factors.
- The multi-pathway pharmacological effects of the volatile oil of ATR are well-aligned with the complex mechanisms of dementia progression, highlighting its significant therapeutic potential for anti-dementia applications.
- This provides new perspectives for the development of more effective anti-dementia drugs.
- Nonetheless, further rigorous and high-quality preclinical and clinical investigations are required to address key issues, including the chemical characterization of the volatile oil of ATR, potential synergistic effects among active ingredients, toxicity profiles, and definitive clinical efficacy.
Why it matters
This review describes how the volatile oil of Acori tatarinowii rhizoma may affect dementia through multiple pathways. The text states that further rigorous preclinical and clinical investigations are required, so no treatment or prevention benefit is established.
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in Pharmacology) |
| Journal's citation record | 2 / 4 | Frontiers in Pharmacology: journal h-index 242 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 4.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jing Chen: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Heilongjiang University of Chinese Medicine: institution h-index 175 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40337511) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fphar.2025.1552801
- PubMed: 40337511
- Original source →
- Free full text: Frontiers in Pharmacology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Inflammation and the immune system from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.